Radionuclide therapy of intractable bone pain: emphasis on strontium-89.
Management of bone pain in patients with multiple osseous metastases is a significant clinical problem. Phosphorus-32 has been used as systemic radioisotope therapy for the management of bone pain for over 40 years. However, significant hematological depression usually results and its use is limited. More recently, the bone-seeking radiopharmaceuticals strontium-89, samarium-153-ethylenediaminetetramethylene phosphonic acid, and rhenium-186-hydroxyethylidene diphosphonate have all been used as palliative treatment for patients with clinically significant bone pain. Excellent clinical responses with acceptable hematological toxicity have been observed. The clinical results rival those of external beam radiation therapy, with fewer systemic and hematological side effects. Systemic radionuclide therapy is indicated in the management of patients with painful metastatic prostate cancer in bone as soon as they escape primary hormonal management. This therapy also should play a role in the management of many patients with advanced breast cancer metastatic to bone. The role of radionuclidic therapy in osseous metastases from other malignancies is still being investigated. These compounds also hold promise as primary therapy for tumors of osseous origin. Systemic radionuclide therapy of painful bony metastases will become common in nuclear medicine practice in the next decade.
Robinson
R G
RG
Department of Diagnostic Radiology, University of Kansas Medical Center, Kansas City 66160-7234.
Preston
D F
DF
Spicer
J A
JA
Baxter
K G
KG
D001859:Bone Neoplasms / Q000503:physiopathology / Q000556:secondary*; D006801:Humans; D010148:Intractable Pain / Q000209:etiology / Q000532:radiotherapy*; D011868:Radioisotopes / Q000627:therapeutic use*; D013326:Strontium Radioisotopes / Q000627:therapeutic use*
D011868:Radioisotopes; D013326:Strontium Radioisotopes